Table 3.
Demographics of patients with Parkinson’s disease categorized by dopaminergic drug treatment
| Drug-naïve (n = 133) | On dopaminergic treatment (n = 55) | p | |
|---|---|---|---|
| Age, yr | 67.9 ± 10.5 | 69.5 ± 10.3 | 0.335 |
| No. of men (%)* | 66 (49.6) | 21 (38.2) | 0.151 |
| Disease duration, yr | 2.0 ± 2.4 | 7.0 ± 4.0 | < 0.001 |
| Hypertension (%)* | 56 (42.1) | 13 (23.6) | 0.017 |
| Diabetes mellitus (%)* | 17 (12.8) | 5 (9.1) | 0.474 |
| Current or ex-smoker (%)* | 30 (22.6) | 5 (9.1) | 0.031 |
| Duration of treatment, yr | - | 6.0 ± 3.6 | |
| Levodopa-equivalent dose, mg | - | 513.5 ± 302.4 | |
| UPDRS | 24.5 ± 18.0 | 34.1 ± 29.5 | 0.021 |
| UPDRS part 1 | 2.4 ± 2.1 | 3.0 ± 2.4 | 0.004 |
| UPDRS part 2 | 7.0 ± 6.2 | 10.9 ± 9.2 | < 0.001 |
| UPDRS part 3 | 15.1 ± 11.6 | 20.1 ± 19.2 | 0.057 |
| Hoehn & Yahr stage | 1.6 ± 0.7 | 2.1 ± 1.0 | < 0.001 |
Values represent the mean with standard deviation or numbers of patients (percentage).
*
analyses were performed by independent sample t-test or by χ2 test.
UPDRS: Unified Parkinson’s Disease Rating Scale.